NICE draft guidance recommends tucatinib for advanced breast cancer
Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading. (Source: NHS Networks)
Source: NHS Networks - February 25, 2022 Category: UK Health Source Type: news
BioPlus Specialty Pharmacy Unveils “Hope Delivered in 24 Hours” for...
Nationwide specialty pharmacy commits to accelerated delivery of generic oncology medication, capecitabine; brings hope and faster time to treatment for patients, including those with metastatic colon...(PRWeb January 25, 2022)Read the full story at https://www.prweb.com/releases/bioplus_specialty_pharmacy_unveils_hope_delivered_in_24_hours_for_oncology_patients/prweb18437382.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 25, 2022 Category: Pharmaceuticals Source Type: news
Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer Pyrotinib Boosts Survival in HER2+ Metastatic Breast Cancer
Patients treated with pyrotinib plus capecitabine survived longer than those treated with lapatinib plus capecitabine in the PHOEBE trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
NICE does not recommend tucatinib for advanced breast cancer
NICE has published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread. (Source: NHS Networks)
Source: NHS Networks - October 27, 2021 Category: UK Health Source Type: news
Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer Perioperative SOX Protocol Bests Adjuvant CapOx in Locally Advanced Gastric Cancer
In patients who had a D2 gastrectomy, perioperative administration of the oral fluoropyrimidine derivative S-1 and oxaliplatin yielded better outcomes than adjuvant capecitabine and oxaliplatin in a phase 3 trial.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
For Residual TNBC Post-Chemo, Capecitabine Should Be Offered For Residual TNBC Post-Chemo, Capecitabine Should Be Offered
For high-risk patients with triple-negative breast cancer who have residual disease following neoadjuvant therapy, Dr Kathy Miller says we must accept capecitabine as the standard of care.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Dr Reddy's Laboratories launches cancer treatment drug Capecitabine in US
The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 17, 2021 Category: Pharmaceuticals Source Type: news
Jury's Still Out on Trifluridine/Tipiracil Plus Bev in mCRC Jury's Still Out on Trifluridine/Tipiracil Plus Bev in mCRC
First-line trifluridine/tipiracil plus bevacizumab offered a slight survival benefit over capecitabine plus bevacizumab in patients with unresectable metastatic colorectal cancer in the TASCO1 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Capecitabine + irinotecan cost effective for colorectal cancer in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2020 Category: Drugs & Pharmacology Source Type: news
CNIO identifies genetic factors associated to hand-foot syndrome in chemotherapy with capecitabine
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * The researchers studied more than 600,000 genetic variants in the genome of 166 patients treated with the chemotherapy drug capecitabine* Before undergoing treatment, the patients carrying the risk alleles for the hand-foot syndrome had low levels of two proteins that are key to the effective functioning of the skin barrier* The finding may help classify patients according to their genetic risk for developing this side effect of some cancer treatments (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 21, 2020 Category: Biology Source Type: news
S-1 + capecitabine cost-effective option in metastatic colorectal cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2020 Category: Drugs & Pharmacology Source Type: news
Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid ca...
Source: Roche Media News - July 14, 2020 Category: Pharmaceuticals Source Type: news
Early Breast Cancer Highlights From ASCO 2020 Early Breast Cancer Highlights From ASCO 2020
Early breast cancer highlights from ASCO 2020 include refinement of adjuvant regimens in HER2+, selection of patients for chemo in ER+, and large-dose capecitabine maintenance in operable TNBC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 24, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news
Tucatinib Combination Induces Positive Intracranial Responses in HER2-Positive Breast Cancer Brain Metastases
Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Lisa Astor Source Type: news
Tucatinib Improves PFS, OS in HER2+ BC With Brain Metastases Tucatinib Improves PFS, OS in HER2+ BC With Brain Metastases
In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 31, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
